The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Imugene (IMU) presents new data from its PD1-Vaxx trial in non-small cell lung cancer patients at the 2022 Study of Lung Cancer annual conference in Vienna
  • The presentation was presented by Professor Michael Boyer of the Chris O’Brien Lifehouse Hospital
  • The study was trialling its immunotherapy drug, IMU-201 or PD1-Vaxx, to determine its safety and tolerability when treating patients with non-small cell lung cancer
  • CEO and Managing Director Leslie Chong says the company is encouraged seeing “positive signals” with correlative biomarker data at such an early stage of the PD1-Vaxx phase one trial
  • Shares in Imugene are up 5.77 per cent to 27.5 cents per share as of 1:02 pm AEST

Imugene (IMU) presented new data from its PD1-Vaxx trial in non-small cell lung cancer patients at the International Association for the Study of Lung Cancer’s annual conference in Vienna.

The presentation was presented by Professor Michael Boyer of the Chris O’Brien Lifehouse Hospital.

The study was trialling its immunotherapy drug, IMU-201 or PD1-Vaxx, to determine its safety and tolerability when treating patients with non-small cell lung cancer.

CEO and Managing Director Leslie Chong said the company is encouraged seeing “positive signals” with correlative biomarker data at such an early stage of the PD1-Vaxx
Phase I trial.

“We are now progressing to the Phase 1b combination studies in treatment naive patients.

“It’s particularly gratifying to have followed a patient in the trial for over 18 months where their tumour burden has been reduced to zero.

“For such a late-stage patient, having a chemo-free alternative could mean a very real difference to their quality of life.”

The phase one trial included different doses, with four patients were in the 10 micrograms per dose cohort, with one patients achieved a complete response, meaning all signs of cancer disappeared due to the treatment.

In the six patient 50 microgram dose cohort, two achieved stable disease, meaning the tumour neither shrunk or grew.

While out of the four patients who received 100-microgram dose

By week six, antibodies to IMU-201 were generated and sustained at high titers during treatment with 100 micrograms of PD1-Vaxx, with a dose dependent increase in antibody production in patients receiving the 100 microgram dose.

Taken together, these data support further evaluation of IMU-201 in NSCLC.

Shares in Imugene were up 5.77 per cent to 27.5 cents per share as of 1:02 pm AEST.

IMU by the numbers
More From The Market Online

The Calmer Co has shipped its Fiji Kava health shots to Australia

The Calmer Co (ASX:CCO) has confirmed its Kava-based health drink products have been shipped to Coles…

The Calmer Co’s FijiKava now at USA’s Walmart

Not long after hitting the shelves at Coles, Calmer Co's Fiji Kava products have hit the…
The Market Online Video

Webinar: Australia’s Uranium Awakening: Investing in a Glowing Future

Uranium's regained serious value after an extended price depression that resulted from plentiful supplies coupled with…

What can we expect from the North American mining sector in 2024?

You may be surprised to learn the USA's nonfuel mining industry contributed US$3.64 trillion towards the…